Browsing Category
Pharma Industry News
4743 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
How UK’s new point-of-care drug manufacturing rules will transform cancer and gene therapies
The UK’s world-first point-of-care manufacturing law transforms advanced therapy delivery—discover how it changes cancer and gene therapy access.
KROMATID collaborates with Cancer Genome in a Bottle consortium to elevate structural standards in cancer genomics
KROMATID joins NIST-led consortium to release first structural cancer genome benchmark; new dataset aims to standardize AI diagnostics and genomics tools.
Sanofi to acquire Vicebio in $1.15bn deal to expand RSV and hMPV vaccine pipeline
Sanofi doubles down on vaccines and rare immunology with Vicebio and Blueprint acquisitions. Find out how these deals could reshape its growth strategy.
Klotho Neurosciences teams up with AAVnerGene to scale gene therapies for Alzheimer’s, ALS, and longevity
Klotho Neurosciences partners with AAVnerGene to accelerate AAV-based gene therapies for Alzheimer’s, ALS, and aging; aims for lower cost and higher precision.
Cooler Heads secures $11m Series A to expand Amma, the FDA-cleared portable scalp cooling device
Cooler Heads raises $11M Series A to scale Amma, its FDA-cleared portable scalp cooling system for chemotherapy hair loss prevention.
NFL Biosciences secures €1.2m non-dilutive funding to accelerate Phase 3 development of NFL-101
Find out how NFL Biosciences secured €1.2 million non-dilutive funding to accelerate Phase 3 of NFL-101, a first-in-class botanical smoking cessation drug.
New non-invasive glaucoma therapy makes U.S. debut at Glaucoma Center of San Francisco
First U.S. patient receives Eyetronic nerve stimulation for glaucoma; early data expected 2026 as non-invasive therapy shows promise.
What makes Ohtuvayre different from Spiriva or Trelegy? Inside the science of dual inhibition
How is Ohtuvayre different from Spiriva and Trelegy? Discover why Merck’s dual PDE3/PDE4 inhibition could change COPD treatment standards.
Texas Cardiac Arrhythmia Institute pioneers U.S. use of FDA-approved leadless cardiac resynchronization system
TCAI becomes first U.S. center to use FDA-approved leadless cardiac resynchronization system; officials hail it as a major advance in heart failure care.
Cloudbreak Pharma’s CBT‑004 Phase 2 success raises hopes for first approved vascularized pinguecula therapy
Cloudbreak Pharma’s CBT‑004 eye drop hit its Phase 2 targets—find out why it could become the first approved vascularized pinguecula therapy by 2028.